Upstream Bio has raised $225 million in an IPO to develop a drug for severe asthma that offers dosing and efficacy advantages over current medications. Investors are optimistic about the company’s potential, leading to an increase in the size of the IPO. Upstream’s drug, verekitug, targets a specific immunological pathway involved in asthma and offers the potential for less frequent dosing. The company is also exploring the drug’s potential in other immunological conditions. Similarly, CAMP4 Therapeutics has raised $75 million in an IPO to develop treatments for haploinsufficiencies using RNA therapy. CeriBell has raised $180.3 million to support the commercialization of its FDA-cleared EEG technology employing AI for seizure detection.
Source link
Aiming to Outdo Rivals in Severe Asthma, Upstream Bio Upsizes IPO to $225M
